Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelcitoclax in SCLC or Advanced Solid Tumors
NCT03387332Phase 1Terminated
- Sponsor
- Ascentage Pharma
- Start
- Dec 2017
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelcitoclax in small cell lung cancer (SCLC) and solid tumor, sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity and Maximum Tolerated Dose. Started Dec 2017; status: terminated.
02
Drugs
pelcitoclax
03
Conditions
small cell lung cancer (SCLC)solid tumor
Beyond the preview
Go deeper on NCT03387332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387332.